Verve Therapeutics, Inc.
NASDAQ:VERV
Overview | Financials
Company Name | Verve Therapeutics, Inc. |
Symbol | VERV |
Currency | USD |
Price | 6.3 |
Market Cap | 533,381,940 |
Dividend Yield | 0% |
52-week-range | 4.305 - 19.34 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Sekar Kathiresan M.D. |
Website | https://www.vervetx.com |
An error occurred while fetching data.
About Verve Therapeutics, Inc.
Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD